|
|
Post by uvula on May 17, 2022 8:23:11 GMT -5
Something doesn't add up. They say this
"We have a track record of successfully inventing and developing novel peptide-based product candidates. This success is based on our deep understanding of peptide chemistry and extensive experience in improving the therapeutic characteristics of naturally-occurring peptides by modifying and optimizing their structures."
But the thing mnkd bought is just a delivery device that uses someone else's insulin.
I can almost picture MC playing poker with the other ceo. If you win I'll buy v-go from you. If I win you buy afrezza from me. Oh crap.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2022 8:24:08 GMT -5
|
|
|
|
Post by hellodolly on May 17, 2022 8:32:54 GMT -5
On April 2, 2020 (or “the acquisition date”) Zealand acquired substantially all of the medical technology business from Valeritas Holdings, Inc. (or “Valeritas”) pursuant to the terms of the stalking horse asset purchase agreement previously entered into with Valeritas and following approval by the U.S. Bankruptcy Court for the District of Delaware on March 20, 2020.
Valeritas was a U.S. based commercial-stage company whose activities comprised development, production and sale of wearable disposable insulin pumps and has therefore been acquired to accelerate Zealand’s plans for establishing U.S. operations to support the anticipated launch of the auto-injector and pre-filled syringe for severe hypoglycemia.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2022 8:34:36 GMT -5
not sure if your conversion is correct. DKK 15.1 million = USD 2.3 million |
|
|
|
Post by akemp3000 on May 17, 2022 8:34:51 GMT -5
IMO...A bit excessive negativity about this small transaction without any supporting or substantive information. It will be good to hear MC describe the foundation for the transaction.
|
|
|
|
Post by mango on May 17, 2022 8:36:18 GMT -5
Some of you are jumping the gun here and perhaps unable to see the bigger picture. This device has been proven via clinical trials to provide significant results. Maybe the problem was the owners never had a good way to market it and didn’t have the tools in order to do so? I believe there is a good cost savings here for the patients as well based on the literature I’ve been reading. Lower cost and less use of insulin with VGO compared to multiple daily injections. We now have a great pair we can use—Afrezza and VGO. Read the studies. Do some basic research on the product before denouncing it. The data speaks for itself. This is a great product. pubmed.ncbi.nlm.nih.gov/31833010/pubmed.ncbi.nlm.nih.gov/33214190/www.ncbi.nlm.nih.gov/pmc/articles/PMC7299448/www.ncbi.nlm.nih.gov/pmc/articles/PMC5960483/ |
|
|
|
Post by awesomo on May 17, 2022 8:40:50 GMT -5
Some of you are jumping the gun here and perhaps unable to see the bigger picture. This device has been proven via clinical trials to provide significant results. Maybe the problem was the owners never had a good way to market it and didn’t have the tools in order to do so?Well this sounds familiar... One company went bankrupt pushing this product, another gave up two years after acquiring it. And it's not like Mike and MannKind have any history of successful marketing/sales campaigns. |
|
|
|
Post by hellodolly on May 17, 2022 8:41:35 GMT -5
not sure if your conversion is correct. DKK 15.1 million = USD 2.3 million This morning DKK $1M was equivalent to $141.3K USD. Revenue from V-GO was DKK $161M in 2021. Not sure what DKK 15.1M came from? DKK $161M X .1413 USD is $22M USD. |
|
|
|
Post by hellodolly on May 17, 2022 8:45:00 GMT -5
Some of you are jumping the gun here and perhaps unable to see the bigger picture. This device has been proven via clinical trials to provide significant results. Maybe the problem was the owners never had a good way to market it and didn’t have the tools in order to do so? I believe there is a good cost savings here for the patients as well based on the literature I’ve been reading. Lower cost and less use of insulin with VGO compared to multiple daily injections. We now have a great pair we can use—Afrezza and VGO. Read the studies. Do some basic research on the product before denouncing it. The data speaks for itself. This is a great product. pubmed.ncbi.nlm.nih.gov/31833010/pubmed.ncbi.nlm.nih.gov/33214190/www.ncbi.nlm.nih.gov/pmc/articles/PMC7299448/www.ncbi.nlm.nih.gov/pmc/articles/PMC5960483/My understanding is Zealand wants to sell their assets to acquire more non-dilutive funding so they can focus on becoming an R&D life sciences company and not have to worry about sales, logistics, marketing, etc. |
|
|
|
Post by awesomo on May 17, 2022 8:47:29 GMT -5
not sure if your conversion is correct. DKK 15.1 million = USD 2.3 million This morning DKK $1M was equivalent to $141.3K USD. Revenue from V-GO was DKK $184M in 2021. Not sure what DKK 15.1M came from? DKK $184M X .1413 USD is $26M USD. Revenue in 2021 was combined V-Go and their new product Zegalogue (commercially available in June 2021). V-Go revenue in 2021 was down compared to 2020 on a monthly revenue basis (only 9 months in 2020). |
|
|
|
Post by hellodolly on May 17, 2022 8:50:57 GMT -5
This morning DKK $1M was equivalent to $141.3K USD. Revenue from V-GO was DKK $184M in 2021. Not sure what DKK 15.1M came from? DKK $184M X .1413 USD is $26M USD. Revenue in 2021 was combined V-Go and their new product Zegalogue (commercially available in June 2021). V-Go revenue in 2021 was down compared to 2020 on a monthly revenue basis (only 9 months in 2020). I corrected my previous post on revenue taken from the 2021 Annual Report. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2022 8:53:49 GMT -5
|
|
|
|
Post by awesomo on May 17, 2022 8:54:49 GMT -5
Revenue in 2021 was combined V-Go and their new product Zegalogue (commercially available in June 2021). V-Go revenue in 2021 was down compared to 2020 on a monthly revenue basis (only 9 months in 2020). I corrected my previous post on revenue taken from the 2021 Annual Report. No, that number is from 2020. Revenue in 2021 of DKK 184.0 million from sale of goods comprise our current two products, V-Go and Zegalogue. In 2020, we recognized DKK 161.3 million as net sales from goods sold generated from our V-Go product.It also says the 2020 numbers are from April to December since the acquisition finalized in April 2020. So those numbers are for 9 months. 2021's total revenue for 12 full months is barely higher and that includes revenue from another product. |
|
|
|
Post by cretin11 on May 17, 2022 8:58:16 GMT -5
Something doesn't add up. They say this "We have a track record of successfully inventing and developing novel peptide-based product candidates. This success is based on our deep understanding of peptide chemistry and extensive experience in improving the therapeutic characteristics of naturally-occurring peptides by modifying and optimizing their structures." But the thing mnkd bought is just a delivery device that uses someone else's insulin. I can almost picture MC playing poker with the other ceo. If you win I'll buy v-go from you. If I win you buy afrezza from me. Oh crap. I’m envisioning the classic picture of the dogs playing poker. Zealand shares are up big this morning, so early returns would support your (facetious I know) poker analogy that our guy might not have gotten the sweetest deal. But it’s too early to draw much conclusion, and at least MNKD shares aren’t getting punished, and thankfully it’s on an up day for the XBI thus far. |
|
|
|
Post by harryx1 on May 17, 2022 8:59:51 GMT -5
For those of you not on ST... "Monomeric Insulin" is the Holy Grail of insulin whether it's Inhaled or liquid (but Inhaled will always be slightly faster than SubQ liquid). They wouldn't be doing research and studies on liquid monomer insulin if it wasn't important. Just read this July 2020 article to see... scitechdaily.com/researchers-develop-a-new-ultrafast-insulin-for-management-of-blood-sugar-in-diabetes/I believe MNKD owns the patent for liquid monomer insulin and I think I remember some comment previously they could make Afrezza into a liquid. I don't know what the rationale behind acquiring V-Go is but an unintended use in the future could come about described above. Also to add more, that IMO MNKD should be seriously looking into converting Afrezza to a liquid if it's possible to also have that option for people that cannot take Afrezza as well as to compete further with the big 3.  |
|
